tbuckley/cabot-search huggingface dataset:
THU0291 Not Only Organ Involvement, but Also Inflammation Level Is Heterogeneous in IGG4-Related Disease: Table 1.
Authors: O. Karadag, U. Kalyoncu, A.S. Ayhan, I. Donmez, L. Kilic, A. Akdogan, B. Akdogan, T. Hazirolan, D.E. Baydar, I. Ertenli, S. Kiraz
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> IgG4-Related Disease (IgG4-RD) is a recently recognized condition with a wide range of organ involvements.Few data exist on the global perspective of IgG4-RD regarding prevalence and the frequencies of the different clinical presentations. <h3>Objectives</h3> This study is aimed to describe the clinical and laboratory characteristics of a series of patients diagnosed with IgG4-RD in Turkey. <h3>Methods</h3> A retrospective study was performed. Demographic, clinical characteristics and imaging studies including PET-CT, in addition to serum IgG4 levels were recorded. Totally 48 pathologic specimens of the patients were re-evaluated regarding IgG4-RD morphologic findings and IgG4/total Ig G ratio. Patients were diagnosed according to diagnostic criteria for IgG4-RD.<sup>1</sup> <h3>Results</h3> Totally 27 patients fulfilling the diagnostic criteria were included in the study, 18 of whom (66.7%) were male. Mean age at diagnosis was 55.9±11.8 years. Retroperitoneal fibrosis is the most common finding. Fourteen (51.8%) of the patients had more than one clinical involvement. Thirty percent of patients had lymphadenopathy. Nine (33.3%) of patients had any additional cardiovascular involvement (thoracic aortitis/inflammatory abdominal aneurisms/coronary periarteritis). The global distribution by specific organ involvement was shown in Table. Three of the patients had normal serum IgG4 levels. Six patients had PET-CT. Patients had a wide range of inflammation assessed by PET-CT (SUV max levels were between 2.2-11.4). Twenty of the patients were pathologically proven IgG4-RD -16 of them had morphologic features and all had a ratio of IgG4/IgG ≥40%. <h3>Conclusions</h3> The most usual presentation of IgG4 related disease in our study is middle aged males and as retroperitoneal fibrosis. Cardiovascular involvement, lymphadenopathy, and orbital/periorbital involvements were the other frequent findings. Not also the organ involvement but also inflammation level could be in a very wide range in IgG4-RD. More collaborative studies are required in order to assess the real prevalence of the disease and the frequencies of the different presentations. <h3>References</h3> Guma M, Firestein GS. IgG4 relateddiseases. Best PractClinRheum 2012;26:425-438. <h3>Disclosure of Interest</h3> None declared
Distress Management
Authors: Jimmie C Holland, Barbara Andersen, William S Breitbart, Luke O Buchmann, Bruce Compas, Teresa L Deshields, Moreen M Dudley, Stewart Fleishman, Caryl D Fulcher, Donna B Greenberg, Carl B Greiner, George F Handzo, Laura Hoofring, Charles Hoover, Paul B Jacobsen, Elizabeth Kvale, Michael H Levy, Matthew J Loscalzo, Randi McAllister-Black, Karen Y Mechanic, Oxana Palesh, Janice P Pazar, Michelle B Riba, Kristin Roper, Alan D Valentine, Lynne I Wagner, Michael A Zevon, Nicole R McMillian, Deborah A Freedman-Cass
Journal: Journal of the National Comprehensive Cancer Network (2013)

The integration of psychosocial care into the routine care of all patients with cancer is increasingly being recognized as the new standard of care. These NCCN Clinical Practice Guidelines in Oncology for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer. They are intended to assist oncology teams identify patients who require referral to psychosocial resources and to give oncology teams guidance on interventions for patients with mild distress to ensure that all patients with distress are recognized and treated.
Reversal of Thiazide-Induced Transient Hyperuricemia by Uricosuric Agents
Authors: Renata P. Smilo, William R. Beisel, Peter H. Forsham
Journal: New England Journal of Medicine (1962)

SINCE their introduction in 1958 the thiazides have had very extensive use in medical practice. Coincident with their wide acceptance, reports began to appear concerning side effects such as hypokalemia,1 2 3 hyperglycemia4 and hyperuricemia.3 , 5 6 7 8 9 10 11 Healey and his associates7 have demonstrated that uricosuric agents can prevent such thiazide-induced uricemia.The present investigation was conducted to determine how effective uricosuric agents were in preventing thiazide hyperuricemia and to what extent they might interfere with the diuretic action. With the use of long-term studies during a constant diet and short-term measurements of renal function normal subjects received thiazide drugs in brief courses, with or . . .
The Natural History of Lone Atrial Fibrillation
Authors: Stephen L. Kopecky, Bernard J. Gersh, Michael D. McGoon, Jack P. Whisnant, David R. Holmes, Duane M. Ilstrup, Robert L. Frye
Journal: New England Journal of Medicine (1987)

From 1950 to 1980, 3623 patients from Olmsted County, Minnesota, were found to have atrial fibrillation. Ninety-seven of these patients (2.7 percent), who were 60 years old or younger at diagnosis, had lone atrial fibrillation (atrial fibrillation in the absence of overt cardiovascular disease or precipitating illness), and their data were reviewed to determine the incidence of thromboemboli. Twenty of these patients (21 percent) had an isolated episode of atrial fibrillation, 56 (58 percent) had recurrent atrial fibrillation, and 21 (22 percent) had chronic atrial fibrillation. The total follow-up period was 1440 person-years, with a mean of 14.8 years per patient. The mean age at diagnosis was 44 years. Nineteen cardiovascular events occurred in 17 patients; 4 patients had strokes thought to be due to emboli from atrial fibrillation, and 4 had myocardial infarctions without overt evidence of previous coronary artery disease. The probability of survival at 15 years was 94 percent among the patients with lone atrial fibrillation. At 15 years, 1.3 percent of the patients had had a stroke on a cumulative actuarial basis. On an actuarial basis, there was no difference in survival or in survival free of stroke among the patients with the three types of lone atrial fibrillation (i.e., isolated, recurrent, and chronic). We conclude that lone atrial fibrillation in patients under the age of 60 at diagnosis is associated with a very low risk of stroke. This suggests that routine anticoagulation may not be warranted.
Prognostic factors for survival of metastatic breast cancer (MBC): A retrospective study from 4,233 women treated in a single institution
Authors: C. Lévy, O. Switsers, J. Ollivier, D. Allouache, C. Delcambre, J. Génot, K. Gunzer, F. Toudic-Emily, C. Segura, T. Delozier
Journal: Journal of Clinical Oncology (2008)

1102 Background: MBC remains an incurable disease, with a median survival of two years. However, some patients experience a substantial longer survival. The aim of this study is to determine the prognostic factors for survival at this stage of the disease. Methods: We collected data from all patients treated in our institution for MBC before 2003. The influence of different parameters concerning the primary breast cancer (tumour size, pathological nodal status, histologic type, tumour grade, oestrogen receptor status, inflammatory breast cancer [IBC]) and the characteristics of MBC (disease-free interval [DFI], type and number of metastatic sites, response to treatment) were studied. Results: We selected 4,233 women. The median age was 58 years at the time of primary breast cancer, 61 years at the time of metastatic relapse. For the overall population, the probability of survival at 2 and 5 years is respectively 25, 3% and 10%. In univariate analysis, DFI, type of metastatic disease (visceral /not visceral) and response to the first-line treatment are the most significant prognostic factors. The prognostic influence of primary tumour characteristics (tumour size and grade, IBC, positive nodal status, hormonal receptor status) remains significant for survival in metastatic disease. In multivariate analysis, all these factors (excepting tumour size and histologic type) remain significant for survival during MBC (table 1). Conclusions: In this large subset of patients, the classical characteristics of metastatic disease are confirmed as significant prognostic factors for survival. However, prognostic factors of primary breast cancer can also significantly influence the survival after metastatic relapse. The pertinence of this information to determine the optimal strategy for MBC remains to define. Prognostic factors in multivariate analysis p Tumour size = 0.28 IBC < 0.003 Histologic type = 0.125 Tumour grade < 0.001 Hormonal status < 0.001 Positive nodal status = 0.001 DFI < 12 mos = 0.014 Type of metastatic site < 0.041 Response to 1st line treatment < 0.001 No significant financial relationships to disclose.
Induction of Hypoxanthine Phosphoribosyltransferase Deficiency in Human U-937 Cells<xref ref-type="fn" rid="FN2">2</xref>
Authors: H J Radzun, M R Parwaresch, H Kreipe
Journal: JNCI Journal of the National Cancer Institute (1986)

The aim of the study was to establish enzyme-deficient mutants of the human permanent cell line U-937. Following chemical mutagenesis with the use of ethyl methanesulfonate, this cell line was chronically exposed to increasing concentrations of the toxic hypoxanthine analogue 6-thioguanine. Cells surviving hypoxanthine-aminopterin-thymidine selective media were separated by glass adherence with the use of 12-O-tetradecanoyl-phorbol-13-acetate. Three mutant clones were established, which have remained hypoxanthine phosphoribosyltransferase (HPRT) deficient for a period of 7 months, as shown by indirect measurements with the use of autoradiography and scintillation counting of cells exposed to [3H]hypoxanthine. Since the phenotypic properties and growth behavior of U-937 cells have remained unaltered after the induced mutation, a highly restricted chromosomal segment coding for HPRT seems to have been mutated.
The Risk of Recurrent Venous Thromboembolism in Patients with an Arg<sup>506</sup>→Gln Mutation in the Gene for Factor V (Factor V Leiden)
Authors: Paolo Simioni, Paolo Prandoni, Anthonie W.A. Lensing, Alberta Scudeller, Corrado Sardella, Martin H. Prins, Sabina Villalta, Francesco Dazzi, Antonio Girolami
Journal: New England Journal of Medicine (1997)

A recently discovered mutation in coagulation factor V (Arg506-->Gln, referred to as factor V Leiden), which results in resistance to activated protein C, is found in approximately one fifth of patients with venous thromboembolism. However, the risk of recurrent thromboembolism in heterozygous carriers of this genetic abnormality is unknown.We searched for factor V Leiden in 251 unselected patients with a first episode of symptomatic deep-vein thrombosis diagnosed by venography. The patients were followed prospectively for a mean of 3.9 years to determine the frequency of recurrent venous thrombosis and pulmonary embolism.Factor V Leiden was found in 41 of the patients (16.3 percent; 95 percent confidence interval, 11.8 to 20.9 percent). The cumulative incidence of recurrent venous thromboembolism after follow-up of up to eight years was 39.7 percent (95 percent confidence interval, 22.8 to 56.5 percent) among carriers of the mutation, as compared with 18.3 percent (95 percent confidence interval, 12.3 to 24.3 percent) among patients without the mutation (hazard ratio, 2.4; 95 percent confidence interval, 1.3 to 4.5; P<0.01).The risk of recurrent thromboembolic events is significantly higher in carriers of factor V Leiden than in patients without this abnormality. Large trials assessing the risk-benefit ratio of long-term anticoagulation in carriers of the mutation who have had a first episode of venous thromboembolism are indicated.
Concepts in the Surgical Treatment of Regional Enteritis
Authors: L. Kraeer Ferguson
Journal: New England Journal of Medicine (1961)

ALTHOUGH Crohn and Ginsburg described and established regional ileitis as an entity in 19321 little if anything is known about the etiologic factors that produce the syndrome. Much has been learned about its pathological features that helps to explain the symptoms and course of the disease, but the primary cause has escaped the clinical observations and researches of many investigators. Without knowledge of the causative factor, treatment must necessarily be symptomatic — in some cases discouragingly unsuccessful or when successful often marred by recurrence.Experience with the disease has given a clear picture of the course of its clinicopathological aspects. . . .
Multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial
Authors: Anders Sommer, Mads Brix Kronborg, Bjarne Linde Nørgaard, Steen Hvitfeldt Poulsen, Kirsten Bouchelouche, Morten Böttcher, Henrik Kjærulf Jensen, Jesper Møller Jensen, Jens Kristensen, Christian Gerdes, Peter Thomas Mortensen, Jens Cosedis Nielsen
Journal: European Journal of Heart Failure (2016)
Association of Sweat Sodium with Arterial-Blood Pressure
Authors: Jorge Quintero-Atencio, Héctor Vásquez-León, Luz Mila Pino-Quintero
Journal: New England Journal of Medicine (1966)

THE salt concentration of the sweat has been observed to be low during acclimatization to heat,1 in patients with primary hyperaldosteronism1 and in normal persons given DCA or ACTH2; it is high in Addison's disease.2 The relative concentrations of the sodium, potassium and chloride ions in the intracellular and extracellular spaces may affect the arteriolar tone.3 There is evidence that renin and angiotensin have a direct effect on sodium exchange at the level of effector cells.4 An excessive secretion of aldosterone in the urine exists in malignant hypertension.5 Direct measurements of aldosterone concentrations in plasma and urine present considerable . . .
Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings
Authors: Bryce A. Seifert, Julianne M. O'Daniel, Krunal Amin, Daniel S. Marchuk, Nirali M. Patel, Joel S. Parker, Alan P. Hoyle, Lisle E. Mose, Andrew Marron, Michele C. Hayward, Christopher Bizon, Kirk C. Wilhelmsen, James P. Evans, H. Shelton Earp, Norman E. Sharpless, D. Neil Hayes, Jonathan S. Berg
Journal: Clinical Cancer Research (2016)

Abstract Purpose: To evaluate germline variants in hereditary cancer susceptibility genes among unselected cancer patients undergoing tumor–germline sequencing. Experimental Design: Germline sequence data from 439 individuals undergoing tumor–germline dyad sequencing through the LCCC1108/UNCseq™ (NCT01457196) study were analyzed for genetic variants in 36 hereditary cancer susceptibility genes. These variants were analyzed as an exploratory research study to determine whether pathogenic variants exist within the germline of patients undergoing tumor–germline sequencing. Patients were unselected with respect to indicators of hereditary cancer predisposition. Results: Variants indicative of hereditary cancer predisposition were identified in 19 (4.3%) patients. For about half (10/19), these findings represent new diagnostic information with potentially important implications for the patient and their family. The others were previously identified through clinical genetic evaluation secondary to suspicion of a hereditary cancer predisposition. Genes with pathogenic variants included ATM, BRCA1, BRCA2, CDKN2A, and CHEK2. In contrast, a substantial proportion of patients (178, 40.5%) had Variants of Uncertain Significance (VUS), 24 of which had VUS in genes pertinent to the presenting cancer. Another 143 had VUS in other hereditary cancer genes, and 11 had VUS in both pertinent and nonpertinent genes. Conclusions: Germline analysis in tumor–germline sequencing dyads will occasionally reveal significant germline findings that were clinically occult, which could be beneficial for patients and their families. However, given the low yield for unexpected germline variation and the large proportion of patients with VUS results, analysis and return of germline results should adhere to guidelines for secondary findings rather than diagnostic hereditary cancer testing. Clin Cancer Res; 22(16); 4087–94. ©2016 AACR. See related commentary by Mandelker, p. 3987
Phase III randomized French multicentric study to evaluate the impact of a localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast irradiation in breast ductal carcinoma in situ (the BONBIS trial).
Authors: D. Azria, D. Cowen, C. Bourgier, B. de la Lande, S. Gourgou-Bourgade, Z. Douadi Gaci, M. Leblanc-Onfroy, I. Latorzeff, O. Pradier, P. Maingon, I. Lecouillard, P. Bontemps, S. Ellis, C. Levy, A. Benyoucef, S. Racadot, H. Laharie-Mineur, P. Lagarde, C. Marchal, C. Lemanski
Journal: Journal of Clinical Oncology (2011)

TPS131
Abstract 11664: The Identification and Hierarchy of Bone Marrow-Derived Artery-Resident Mesodermal Progenitor Cells and Their Dynamics in Atherosclerosis
Authors: Hyun-Jai Cho, Hyun-Ju Cho, Yoo-Wook Kwon, Young-Bae Park, Hyo-Soo Kim
Journal: Circulation (2014)

Background: We recently identified bone marrow (BM)-derived artery resident calcifying progenitor cells. Sca-1+PDGFRα- cells may possess bipotent (osteoblastic/osteoclastic) characteristics. However, the nature of progenitor cells remains elusive. Hypothesis: We investigated developmental hierarchy of progenitor cells and in vivo dynamics in atherosclerosis. Methods and Results: We harvested cells from BM and artery of C57 mice. In BM, Lin-CD29+Sca-1+PDGFRα- cells showed hematopoietic potential and differentiated into osteoclasts (OC). They also possessed mesenchymal stem cell property including osteoblastic (OB) differentiation, suggesting that Sca-1+PDGFRα- cells could be mesodermal progenitor cells. Interestingly, BM-derived artery-resident, clonal Sca-1+PDGFRα- cells maintained bipotency but lost hematopoietic nature. In contrast, Sca-1+PDGFRα+ cells in BM and artery only showed unipotency (OB). When we overexpressed or knocked down PDGFRα, there was no alteration in OB or OC differentiation of Sca-1+PDGFRα- cells and no effect on OB differentiation of Sca-1+PDGFRα+ cells, indicating PDGFRα as a surface marker but not a functional player. In hyperlipidemic ApoE-KO mice compared with control, Sca-1+PDGFRα- cells were less mobilized from BM to peripheral circulation and less infiltrated into atherosclerotic plaque, whereas Sca-1+PDGFRα+ cells were not significantly affected. Multiplex cytokine assay of serum and artery revealed that IL-1β was significantly increased and IL-5 was markedly decreased in atherosclerotic mice. IL-1β decreased the migration of Sca-1+PDGFRα- cells by 5 folds compared with TNFα, and IL-5 increased the migration as much as TNFα. But the migration of Sca-1+PDGFRα+ cells was not altered. These data indicate that atherosclerosis-related humoral factors mainly regulated mesodermal progenitor cells’ dynamics. Conclusion: We demonstrate that Sca-1+PDGFRα- cell is a mesodermal progenitor cell that possesses both hematopoietic and mesenchymal potentials. In atherogenesis, the mobilization and infiltration of Sca-1+PDGFRα- progenitor cells were regulated by IL-1β and IL-5. These data provide a novel mechanism regarding the role of bipotent progenitor cells in atherosclerosis.
P258 Multi-Drug Resistant Tuberculosis Monitoring Guidance: Are we following the national guidelines?: Abstract P258 Table 1
Authors: S Parmar, R Singal, H Khachi
Journal: Thorax (2015)

<h3>Introduction</h3> Multi-Drug Resistant Tuberculosis (MDR-TB) is a form of TB that is resistant to the two most powerful first-line anti-tuberculosis antibiotics available, rifampicin and isoniazid. Between 2004 and 2011, the proportion of cases with MDR-TB increased from 1.2% to 1.6%, of which it has remained stable over the past 3 years. Due to the complexity of treatment regimens used for MDR-TB, national monitoring guidelines have been developed to aid monitoring for adverse effects during treatment.<sup>1</sup> A previous study identified that prior to the development of these monitoring guidelines the incidence of adverse effects associated with MDR TB medicines was high.<sup>2</sup> <h3>Objective</h3> To establish whether national guidelines for the monitoring of MDR-TB medicines at a tertiary centre are being adhered to. <h3>Results</h3> 9 patients with MDR-TB were included in the audit. The findings (see Table 1) show that baseline monitoring was not undertaken in the majority of patients. Whilst on-going monitoring was predominantly undertaken in over 80% of occasions, the audit standard was not met. <h3>Conclusions</h3> Despite the presence of national guidance to support the monitoring of complex regimens for MDR-TB, this audit shows that monitoring of these in a tertiary centre is below the audit standard. Whilst adherence to on-going monitoring parameters were usually undertaken in over 80% of instances, it is of particular concern that baseline monitoring was significantly below the audit standard. Pharmacists are ideally placed to support the safe and effective monitoring of these often toxic medicines. The development of a pharmacist to support the TB clinics and specifically to support the monitoring of patients with MDR-TB could significantly improve this adherence and reduce the risk of adverse effects as a result of sub-optimal monitoring. <h3>References</h3> 1 Potter JL, Capstick T. A UK based resource to support the monitoring and safe use of anti-tuberculosis drugs and second line treatment of multi-drug resistant tuberculosis. First published May 2014, Latest update January 2015 2 Keal JL, Khachi H, Hanzaree E, <i>et al</i>. Treatment of multidrug resistant tuberculosis: where are the guidelines for monitoring? <i>Thorax</i> 2011;<b>66</b>(Suppl 4):A91
Rheumatoid Spondylitis and Aortic Insufficiency
Authors: Donald P. Schilder, W. Proctor Harvey, Charles A. Hufnagel
Journal: New England Journal of Medicine (1956)

HEART disease associated with rheumatoid spondylitis (Marie–Strümpell arthritis) has been a subject of interest for many years.1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Pericarditis,6 , 7 , 10 , 13 , 15 16 17 myocarditis3 , 12 , 16 , 17 and particularly endocarditis with valvulitis1 2 3 4 5 6 7 , 9 10 11 12 13 , 15 16 17 have been reported. Involvement of the mitral and aortic valves has been described, but aortic-valve disease, particularly with aortic insufficiency, is apparently more common.10 , 11 , 13 , 16 17 18 Conduction disturbances, either as isolated defects or in conjunction with other evidence of heart disease, have also been observed.8 , 10 , 11 , 14 It has been stated that the heart disease in rheumatoid spondylitis characteristically follows an episode of acute polyarthritis,1 2 3 , 10 , 11 is more common in patients in whom chronic peripheral rheumatoid arthritis develops with the onset . . .
Assessing the potential risk of Zika virus epidemics in temperate areas with established Aedes albopictus populations
Authors: Giorgio Guzzetta, Piero Poletti, Fabrizio Montarsi, Frederic Baldacchino, Gioia Capelli, Annapaola Rizzoli, Roberto Rosà, Stefano Merler
Journal: Eurosurveillance (2016)

Based on 2015 abundance of Aedes albopictus in nine northern Italian municipalities with temperate continental/oceanic climate, we estimated the basic reproductive number R0 for Zika virus (ZIKV) to be systematically below the epidemic threshold in most scenarios. Results were sensitive to the value of the probability of mosquito infection after biting a viraemic host. Therefore, further studies are required to improve models and predictions, namely evaluating vector competence and potential non-vector transmissions.